Investigation of the Prevalence and Number of Aberrant Crypt Foci Associated with Human Colorectal Neoplasm

被引:29
|
作者
Sakai, Eiji
Takahashi, Hirokazu
Kato, Shingo
Uchiyama, Takashi
Hosono, Kunihiro
Endo, Hiroki
Maeda, Shin
Yoneda, Masato
Taguri, Masataka [2 ]
Nakajima, Atsushi [1 ]
机构
[1] Yokohama City Univ, Sch Med, Div Gastroenterol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan
[2] Yokohama City Univ, Sch Med, Dept Biostat & Epidemiol, Yokohama, Kanagawa 2360004, Japan
关键词
PRENEOPLASTIC LESIONS; CIGARETTE-SMOKING; CANCER; ALCOHOL; RISK; COLON; QUANTIFICATION; PREVENTION; ADENOMA; TOBACCO;
D O I
10.1158/1055-9965.EPI-11-0104
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Aberrant crypt foci (ACF) are considered to be useful as surrogate biomarker for colorectal cancer (CRC), but the biological significance of ACF remains controversial. We attempted to investigate the relationship between the presence of ACF and human colorectal carcinogenesis using a relatively large sample size. Methods: We carried out high-magnification chromoscopic colonoscopy to identify ACFs in 861 subjects undergoing a diagnostic endoscopy at the Yokohama City University Hospital. The present study compared the prevalence and number of ACFs in three subject groups (normal subjects, adenoma cases, and CRC cases). The correlations between the demographic and behavioral characteristics of the subjects and the prevalence of ACFs were also assessed. Results: The prevalence of ACF was 64%, 88%, and 95%, and the mean number of ACF was 3.6, 6.2, and 10.1, in normal subjects, adenoma cases, and CRC cases, respectively. When differences in the prevalence and number of ACFs among age- and sex-stratified subject groups were examined, significant stepwise increments from normal subjects to adenoma cases to CRC cases were apparent (P < 0.001). Moreover, an age-and sex-adjusted multiple logistic regression analysis revealed that smoking and alcohol habits had a synergistic effect, increasing the prevalence of ACFs as well as the risk of CRC (P < 0.001). Conclusions: These results suggested that ACF may serve as a reliable surrogate biomarker for human colorectal carcinogenesis. Impact: The use of ACF as an endpoint may enable the size, duration, and cost of CRC chemoprevention studies to be reduced. Cancer Epidemiol Biomarkers Prev; 20(9); 1918-24. (C)2011 AACR.
引用
收藏
页码:1918 / 1924
页数:7
相关论文
共 47 条
  • [1] Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy
    Anderson, Joseph C.
    Swede, Helen
    Rustagi, Tarun
    Protiva, Petr
    Pleau, Devon
    Brenner, Bruce M.
    Rajan, Thiruchandurai V.
    Heinen, Christopher D.
    Levine, Joel B.
    Rosenberg, Daniel W.
    CANCER CAUSES & CONTROL, 2012, 23 (02) : 355 - 361
  • [2] Number of aberrant crypt foci in the rectum is a useful surrogate marker of colorectal adenoma recurrence
    Uchiyama, Takashi
    Takahashi, Hirokazu
    Endo, Hiroki
    Kato, Shingo
    Sakai, Eiji
    Hosono, Kunihiro
    Yoneda, Masato
    Inamori, Masahiko
    Hippo, Yoshitaka
    Nakagama, Hitoshi
    Nakajima, Atsushi
    DIGESTIVE ENDOSCOPY, 2012, 24 (05) : 353 - 357
  • [3] Aberrant crypt foci as biomarkers predictive of colorectal carcinoma
    Perse, Martina
    Mlinaric, Vladimir
    Cerar, Anton
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2010, 79 (06): : 499 - 506
  • [4] Association between factors associated with colorectal cancer and rectal aberrant crypt foci in humans
    Ezuka, Akiko
    Sakai, Eiji
    Kawana, Kenichi
    Nagase, Hajime
    Kakuta, Yukio
    Uchiyama, Shiori
    Ohkubo, Hidenori
    Higurashi, Takuma
    Nonaka, Takashi
    Endo, Hiroki
    Takahashi, Hirokazu
    Nakajima, Atsushi
    ONCOLOGY LETTERS, 2015, 10 (06) : 3689 - 3695
  • [5] The distribution of human rectal aberrant crypt foci and criteria for defining the counting area
    Fujii, Tetsuro
    Sakai, Eiji
    Takahashi, Hirokazu
    Yamada, Eiji
    Ohkubo, Hidenori
    Higurashi, Takuma
    Nakajima, Atsushi
    ONCOLOGY LETTERS, 2017, 13 (06) : 4501 - 4504
  • [6] Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial
    Hosono, Kunihiro
    Endo, Hiroki
    Takahashi, Hirokazu
    Sugiyama, Michiko
    Sakai, Eiji
    Uchiyama, Takashi
    Suzuki, Kaori
    Iida, Hiroshi
    Sakamoto, Yasunari
    Yoneda, Kyoko
    Koide, Tomoko
    Tokoro, Chikako
    Abe, Yasunobu
    Inamori, Masahiko
    Nakagama, Hitoshi
    Nakajima, Atsushi
    CANCER PREVENTION RESEARCH, 2010, 3 (09) : 1077 - 1083
  • [7] Natural history of human aberrant crypt foci and correlation with risk factors for colorectal cancer
    Ohkubo, Hidenori
    Takahashi, Hirokazu
    Yamada, Eiji
    Sakai, Eiji
    Higurashi, Takuma
    Uchiyama, Takashi
    Hosono, Kunihiro
    Endo, Hiroki
    Taguri, Masataka
    Nakajima, Atsushi
    ONCOLOGY REPORTS, 2012, 27 (05) : 1475 - 1480
  • [8] A Multicenter Study of Prevalence and Risk Factors for Aberrant Crypt Foci
    Mutch, Matthew G.
    Schoen, Robert E.
    Fleshman, James W.
    Rall, Christopher J. N.
    Dry, Sarah
    Seligson, David
    Charabaty, Aline
    Chia, David
    Umar, Asad
    Viner, Jaye
    Hawk, Ernest
    Pinsky, Paul F.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (05) : 568 - 574
  • [9] Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability
    Swede, Helen
    Rohan, Thomas E.
    Yu, Herbert
    Anderson, Joseph C.
    Stevens, Richard G.
    Brokaw, Jane
    Levine, Joel
    Brenner, Bruce M.
    Malchoff, Carl D.
    Duffy, Valerie B.
    Pleau, Devon C.
    Rosenberg, Daniel W.
    CANCER CAUSES & CONTROL, 2009, 20 (05) : 653 - 661
  • [10] Methylation study of tumor suppressor genes in human aberrant crypt foci, colorectal carcinomas, and normal colon
    Sarangi, Jayati
    Das, Prasenjit
    Ahmad, Aijaz
    Sulaiman, Mohamed
    Ghosh, Shouriyo
    Gupta, Brijnandan
    Panwar, Rajesh
    Pal, Sujoy
    Yadav, Rajni
    Ahuja, Vineet
    Sen, Sudip
    Upadhyay, Asish D.
    Dash, Nihar R.
    Sharma, Atul
    Gupta, Siddhartha D.
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (01) : 268 - 274